Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities

Abstract

Background:

Molecular testing is crucial for the implementation of personalized therapy in patients with lung cancer. Whether routine biomarker testing and access to personalized therapies are limited in some Italian regions is unclear.

Patients and Methods:

We conducted a national cross-sectional survey between April and June 2019 among Italian oncologists to determine differences in biomarker testing and access to personalized therapies for lung cancer.

Results:

Based on GIMBE report n. 3/2018, 32 respondents (37.6%) were defined as belonging to budget deficit regions (BDRs) while 53 (62.4%) were from balanced/positive budget regions (BPRs). Diagnostic assays for EGFR/ALK/ROS1 and PD-L1 were reported to be available in 47/53 (88.7%) and 22/32 (68.85%) centers from BPRs and BDRs, respectively (p=0.04).

Liquid biopsy accessibility was wider in BPRs than in BDRs (75.5% (40/53) vs. 50% (16/32), respectively; p=0.03). 84/85 (98.8%) oncologists reported that ⩾75% of eligible patients received first-line targeted therapies. Reason for not administering first-line targeted therapies was defined as clinically-unrelated (molecular testing not available or incomplete, pharmacoeconomic issues) by 25/42 (59.5%) of respondents from BPRs and 21/26 (80.6%) from BDRs (p=0.12). Reason for not administering first-line pembrolizumab was defined as clinically-unrelated by 8/43 (18.6%) of respondents from BPRs and 10/22 (45.4%) from BDRs (p=0.039).

Conclusion:

Disparities in access to diagnostic assay and first line immunotherapy exist between BPRs and BDRs.

Keywords

Non-small cell lung cancer survey accessibility health migration personalized therapy

Get full access to this article

View all access options for this article.

References

AIOM, I Numeri del cancro in Italia 2020, Oct 2020, https://www.aiom.it/i-numeri-del-cancro-in-italia/ (accessed 18 August 2021).

Rocco

Battiloro

Gravara

L Della

, et al. Advanced non-small cell lung cancer with activating epidermal growth factor receptor mutation: first line treatment and beyond. Rev Recent Clin Trials. 2019;14(2):120-128.

Dietel

Bubendorf

Dingemans

AMC

, et al. Diagnostic procedures for non-small-cell lung cancer (NSCLC): Recommendations of the European Expert Group. Thorax. 2016;71(2):177-184.

Kerr

Bubendorf

Edelman

, et al. Second ESMO consensus conference on lung cancer: Pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol. 2014;25(9):1681-1690.

Remon

Tabbò

Jimenez

, et al. Sequential blinded treatment decisions in ALK-positive non-small cell lung cancers in the era of precision medicine. Clin Transl Oncol. 2020;22(9):1425-1429.

Reck

Rodríguez-Abreu

Robinson

, et al. Pembroli-zumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823-1833.

Sequist

LV.

Waltman

Dias-Santagata

, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26-75ra26.

Mok

Ahn

, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-Positive lung cancer. N Engl J Med. 2017;376(7):629-640.

Planchard

, et al. Pan-asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: A csco-esmo initiative endorsed by jsmo, ksmo, mos, sso and tos. Ann Oncol. 2019; 30(2):171-210.

10.

Wang

Herbst

Boshoff

Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27(8):1345-1356.

11.

Ragazzi

Tamagnini

Bisagni

, et al. Diamond: Immunohistochemistry versus sequencing in EGFR analysis of lung adenocarcinomas. J Clin Pathol. 2016;69(5):440-7.

12.

Rimm

Han

Taube

, et al. A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non–small cell lung cancer. JAMA Oncol. 2017;3(8):1051-1058.

13.

Tsao

Hirsch

Yatabe

, et al (eds). IASLC Atlas of ALK and ROS1 Testing in Lung Cancer. Aurora, CO: IASLC, 2016.

14.

Mok

Carbone

Hirsch

, et al (eds). IASLC Atlas of EGFR Testing in Lung Cancer. Aurora, CO: Rx Press Printing, 2017.

15.

Lindeman

Cagle

Aisner

, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors guideline from the college of American pathologists, the international association for the study of lung cancer, and the association for molecular pathology. Arch Pathol Lab Med. 2018;142(3):321-346.

16.

Malone

Oliva

Sabatini

PJB

, et al. Molecular profiling for precision cancer therapies. Genome Med. 2020; 12(1):8.

17.

Kalemkerian

Narula

Kennedy

, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American society of clinical oncology endorsement of the college of American pathologists/ international association for the study of lung cancer/ association for molecular pathology clinical practice guideline update. J Clin Oncol. 2018;36(9):911-919.

18.

Díaz-Serrano

Gella

Jiménez

, et al. Targeting EGFR in lung cancer: current standards and developments. Drugs. 2018;78(9):893-911.

19.

Lee

Tsao

Kambartel

, et al. Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study. PLoS One. 2018; 13(8):e0202865.

20.

Mainil

Van Loon

Dinnie

, et al.Transnational health care: From a global terminology towards transnational health region development. Health Policy. 2012;108(1):37-44.

21.

Koylu

Delil

Guo

Celik

RN.

Analysis of big patient mobility data for identifying medical regions, spatio-temporal characteristics and care demands of patients on the move. Int J Health Geogr. 2018;17(1):32.

22.

Report Osservatorio GIMBE n.3/2018. La mobilità sanitaria interregionale nel 2017, www.gimbe.org/mobilita2017 (2018, accessed 18 August 2021).

23.

AIOM, AIOM Libro Bianco 2017. https://www.aiom.it/libro-bianco-2017/ (2017, accessed 18 August 2021).

24.

Olsson

Schultz

Gould

MK.

Timeliness of care in patients with lung cancer: A systematic review. Thorax. 2009 64:749-756.

25.

NHS, Implementing a timed lung cancer diagnostic pathway. https://www.england.nhs.uk/wp-content/uploads/2018/04/implementing-timed-lung-cancer-diagnostic-pathway.pdf (2018, accessed 18 August 2021).

26.

Gobbini

Galetta

Tiseo

, et al. Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study. Lung Cancer. 2017;111:30-37.

27.

AIOM, Linee guida AIOM Neoplasie del polmone 2019. https://www.aiom.it/linee-guida-aiom-neoplasie-del-polmone-2019/ (accessed 18 August 2021).

28.

Presley

Tang

Soulos

, et al. Association of broad-based genomic sequencing with survival among patients with advanced non–small cell lung cancer in the community oncology setting. JAMA - J Am Med Assoc. 2018; 320(5):469-477.

29.

Pennell

Mutebi

Zhou

Z-Y

, et al. Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non–small-cell lung cancer using a decision analytic model. JCO Precis Oncol. 2019;3:1-9.

30.

Cheema

Menjak

Winterton-Perks

, et al. Impact of reflex EGFR / ALK testing on time to treatment of patients with advanced nonsquamous non–small-cell lung cancer. J Oncol Pract. 2017;13(2):e130-e138.

31.

Rolfo

Mack

Scagliotti

, et al. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021;16(10):1647-1662.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.19 MB